Controversies in the management of germ cell tumours of the ovary

Current Opinion in Oncology

Volumn 18, Issue 5, 2006, Pages 500-506

  Patterson, Daniel M ^a   Rustin, Gordon J S ^a  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

Chemotherapy; Histology; Ovarian germ cell tumour; Surgery; Surveillance

Indexed keywords

ALKALINE PHOSPHATASE PLACENTA ISOENZYME; ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; BLEOMYCIN; CA 125 ANTIGEN; CARBOPLATIN; CELL ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; LACTATE DEHYDROGENASE; METHOTREXATE; OCTAMER TRANSCRIPTION FACTOR 4; TUMOR MARKER; VINCRISTINE;

ABDOMINAL HYSTERECTOMY; ADJUVANT CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR RISK; CLINICAL TRIAL; CYSTECTOMY; DIFFERENTIAL DIAGNOSIS; DYSGERMINOMA; FERTILITY; GERM CELL TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; MALIGNANT TRANSFORMATION; PREDICTION; PREGNANCY; PRIORITY JOURNAL; RELAPSE; REVIEW; SALPINGOOOPHORECTOMY; SALVAGE THERAPY; TERATOMA; TUMOR CLASSIFICATION; TUMOR VOLUME;

FEMALE; HUMANS; NEOPLASMS, GERM CELL AND EMBRYONAL; OVARIAN NEOPLASMS; PREGNANCY; TUMOR MARKERS, BIOLOGICAL;

EID: 33746908531     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000239891.44031.38     Document Type: Review

References (58)

1. Quirk JT, Natarajan N. Ovarian cancer incidence in the United States. Gynecol Oncol 2005; 97:519-523.
2. You W, Dainty LA, Rose GS, et al. Gynecologic malignancies in women aged less than 25 years. Obstet Gynecol 2005; 105:1405-1409. Shows the importance of considering the diagnosis of OGCT in young women.
3. Deligeoroglou E, Eleftheriades M, Shiadoes V, et al. Ovarian masses during adolescence: clinical, ultrasonographic and pathologic findings, serum tumor markers and endocrinological profile. Gynecol Endocrinol 2004; 19:1-8.
4. De Backer A, Madern GC, Oosterhuis JW, et al. Ovarian germ cell tumors in children: a clinical study of 66 patients. Pediatr Blood Cancer 2006; 46:459-464. This interesting paper demonstrates that mature teratomas are most common in young girls with an excellent prognosis.
5. Vitaliani R, Mason W, Ances B, et al. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann Neurol 2005; 58: 594-604. This paper presents an interesting series of patients with limbic encephalitis and ovarian teratoma.
6. Matthew R, Christopher O, Philippa S. Severe malignancy-associated hypercalcemia in dysgerminoma. Pediatr Blood Cancer 2005 (epub ahead of print).
7. Gucer F, Oz-Puyan F, Mulayim N, Yuce MA. Ovarian dysgerminoma associated with Pseudo-Meigs' syndrome and functioning ovarian stroma: a case report. Gynecol Oncol 2005; 97:681-684.
8. Khan J, McClennan BL, Qureshi S, et al. Meigs syndrome and gliomatosis peritonei: a case report and review of literature. Gynecol Oncol 2005; 98: 313-317.
9. Bridgewater JA, Rustin GJ. Management of nonepithelial ovarian tumours. Oncology 1999; 57:89-98.
10. Guida M, Mandato VD, Di Spiezio Sardo A, et al. Coexistence of Graves' disease and benign struma ovarii in a patient with marked ascites and elevated CA-125 levels. J Endocrinol Invest 2005; 28:827-830.
11. Loizzi V, Cormio G, Resta L, et al. Pseudo-Meigs syndrome and elevated CA125 associated with struma ovarii. Gynecol Oncol 2005; 97:282-284.
12. Leiserowitz GS, Xing G, Cress R, et al. Adnexal masses in pregnancy: how often are they malignant? Gynecol Oncol 2005 (epub ahead of print). This paper shows how rare ovarian malignancies are during pregnancy. Both maternal and neonatal outcomes are not adversely affected.
13. Aoki Y, Higashino M, Ishii S, Tanaka K. Yolk sac tumor of the ovary during pregnancy: a case report. Gynecol Oncol 2005; 99:497-499. An encouraging case report of the use of tumour marker AFP-L2 to help detect early relapse during pregnancy.
14. Suprasert P, Khunamornpong S, Siriaunkgul S, et al. Ruptured mature cystic teratomas mimicking advanced stage ovarian cancer: a report of 2 cases study. J Med Assoc Thai 2004; 87:1522-1525.
15. Powell JL, Stinson JA, Connor GP, et al. Squamous cell carcinoma arising in a dermoid cyst of the ovary. Gynecol Oncol 2003; 89:526-528.
16. Yamanaka Y, Tateiwa Y, Miyamoto H, et al. Preoperative diagnosis of malignant transformation in mature cystic teratoma of the ovary. Eur J Gynaecol Oncol 2005; 26:391-392. This paper demonstrated that squamous cell antigen and tumour size may predict risk of malignant transformation of mature teratomas.
17. Zanagnolo V, Sartori E, Galleri G, et al. Clinical review of 55 cases of malignant ovarian germ cell tumors. Eur J Gynaecol Oncol 2004; 25:315-320.
18. Gershenson DM. Fertility-sparing surgery for malignancies in women. J Natl Cancer Inst Monogr 2005; 34:43-47.
19. Zanetta G, Bonazzi C, Cantu M, et al. Survival and reproductive function after treatment of malignant germ cell ovarian tumors. J Clin Oncol 2001; 19:1015-1020.
20. Zanagnolo V, Sartori E, Trussardi E, et al. Preservation of ovarian function, reproductive ability and emotional attitudes in patients with malignant ovarian tumors. Eur J Obstet Gynecol Reprod Biol 2005; 123:235-243.
21. Billmire D, Vinocur C, Rescorla F, et al. Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study. J Pediatr Surg 2004; 39:424-429.
22. Beiner ME, Gotlieb WH, Korach Y, et al. Cystectomy for immature teratoma of the ovary. Gynecol Oncol 2004; 93:381-384.
23. Munkarah A, Gershenson DM, Levenback C, et al. Salvage surgery for chemorefractory ovarian germ cell tumors. Gynecol Oncol 1994; 55:217-223.
24. Rezk Y, Sheinfeld J, Chi DS. Prolonged survival following salvage surgery for chemorefractory ovarian immature teratoma: a case report and review of the literature. Gynecol Oncol 2005; 96:883-887. This case report demonstrates the usefulness of salvage surgery in chemorefractory cases.
25. Wu X, Han LY, Xu X, Li Z. Recurrent immature teratoma of the ovary: a case report of radical secondary cytoreduction with replacement of the aortic bifurcation. Gynecol Oncol 2004; 95:746-749.
26. Tejura H, O'Leary A. Growing teratoma syndrome after chemotherapy for germ cell tumour of the ovary. J Obstet Gynaecol 2005; 25:296-297.
27. Umekawa T, Tabata T, Tanida K, et al. Growing teratoma syndrome as an unusual cause of gliomatosis peritonei: a case report. Gynecol Oncol 2005; 99:761-763.
28. Benoit MF, Hannigan EV, Strickland JL. Recurrent mature cystic ovarian teratoma in adolescence: atypical case of the growing teratoma syndrome. Obstet Gynecol 2005; 105:1264-1266.
29. Rekha W, Amita M, Sudeep G, et al. Growing teratoma syndrome in germ cell tumour of the ovary: a case report. Aust N Z J Obstet Gynaecol 2005; 45:170-171.
30. Ulbright TM. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues. Mod Pathol 2005; 18 (Suppl 2):S61-S79. A good review outlining several problems encountered in making the histological diagnosis of germ cell tumours.
31. O'Connor DM, Norris HJ. The influence of grade on the outcome of stage I ovarian immature (malignant) teratomas and the reproducibility of grading. Int J Gynecol Pathol 1994; 13:283-289.
32. Cho NH, Kim YT, Lee JH, et al. Diagnostic challenge of fetal ontogeny and its application on the ovarian teratomas. Int J Gynecol Pathol 2005; 24:173-182.
33. Looijenga LH, Stoop H, de Leeuw HP, et al. POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res 2003; 63:2244-2250.
34. Cheng L, Thomas A, Roth LM, et al. OCT4: a novel biomarker for dysgerminoma of the ovary. Am J Surg Pathol 2004; 28:1341-1346.
35. Sever M, Jones TD, Roth LM, et al. Expression of CD117 (c-kit) receptor in dysgerminoma of the ovary: diagnostic and therapeutic implications. Mod Pathol 2005; 18:1411-1416. This study demonstrates expression of CD117 in dysgerminomas that is comparable to seminomas.
36. Paule B. KIT receptor in testicular seminoma. Prog Urol 2005; 15:96-99.
37. Dark GG, Bower M, Newlands ES. Surveillance policy for stage I ovarian germ cell tumours. J Clin Oncol 1997; 15:620-624.
38. Marina NM, Cushing B, Giller R, et al. Complete surgical excision is effective treatment for children with immature teratomas with or without malignant elements: a Pediatric Oncology Group/Children's Cancer Group Intergroup Study. J Clin Oncol 1999; 17:2137-2143.
39. Lu KH, Gershenson DM. Update on the management of ovarian germ cell tumors. J Reprod Med 2005; 50:417-425.
40. Williams S, Blessing JA, Liao SY, et al. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group. J Clin Oncol 1994; 12:701-706.
41. Segelov E, Campbell J, Ng M, et al. Cisplatin-based chemotherapy for ovarian germ cell malignancies: the Australian experience. J Clin Oncol 1994; 12: 378-384.
42. PDQ Adult Treatment Editorial Board. Ovarian germ cell tumors (PDQ): treatment. 2004. http://www.nci.nih.gov/cancertopics/pdq. Last accessed 27 April 2006.
43. Dimopoulos MA, Papadimitriou C, Hamilos G, et al. Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study. Gynecol Oncol 2004; 95:695-700.
44. Terzic M, Dokic M, Stimec B. Immature ovarian teratoma in a young girl: very short course and lethal outcome. A case report. Int J Gynecol Cancer 2005; 15:382-384.
45. Roeleveld TA, Horenblas S, Meinhardt W, et al. Surveillance can be the standard of care for stage I nonseminomatous testicular tumors and even high risk patients. J Urol 2001; 166:2166-2170.
46. Boshoff C, Begent RH, Oliver RT, et al. Secondary tumours following etoposide containing therapy for germ cell cancer. Ann Oncol 1995; 6: 35-40.
47. Travis LB, Fossa SD, Schonfeld SJ, et al. Second cancers among 40 576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005; 97:1354-1365.
48. Huddart RA, Norman A, Shahidi M, et al. Cardiovascular disease as a longterm complication of treatment for testicular cancer. J Clin Oncol 2003; 15: 1513-1523.
49. Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 1996; 14: 2923-2932.
50. de Vos FY, Nuver J, Willemse PH, et al. Long-term survivors of ovarian malignancies after cisplatin-based chemotherapy; cardiovascular risk factors and signs of vascular damage. Eur J Cancer 2004; 40:696-700.
51. Schmoll HJ, Souchon R, Krege S, et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004; 15:1377-1399.
52. Lai CH, Chang TC, Hsueh S, et al. Outcome and prognostic factors in ovarian germ cell malignancies. Gynecol Oncol 2005; 96:784-791. Follow-up study hinting that high-dose chemotherapy may play a role in relapsed patients.
53. Bower M, Newlands ES, Holden L, et al. Treatment of men with metastatic nonseminomatous germ cell tumours with cyclical POMB/ACE chemotherapy. Ann Oncol 1997; 8:477-483.
54. Christian JA, Huddart RA, Norman A, et al. Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors. J Clin Oncol 2003; 21:871-877.
55. Bower M, Fife K, Holden L. Chemotherapy for ovarian germ cell tumours. Eur J Cancer 1996; 32A:593-597.
56. Williams SD, Kauderer J, Burnett AF, et al. Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group. Gynecol Oncol 2004; 95:496-499.
57. Horwich A, Sleijfer DT, Fossa SD, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 1997; 15:1844-1852.
58. Oliver RT, Mason MD, Mead GM, et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 2005; 366:293-300. A landmark study showing that adjuvant carboplatin is a safe and effective alternative to radiotherapy in stage I testicular seminomas, the results of which can be applied to dysgerminoma patients not suitable for close surveillance.